Characterization of Mew Breast Tumor-Specific Antigens Using a Novel Antigen Discovery System
Abstract
We have devised a novel tumor antigen discovery system that utilizes dendritic cells (DCs) as antigen-presenting cells to prime naive T cells against peptides and proteins isolated from a breast tumor cell line (MS) that does not express both the known breast tumor-specific antigens, MUC-1 and Her-2/neu. We isolated HLA Class I molecules from the tumor, and acid-extracted the peptides bound to the HLA Class I molecules. The peptides were then fractionated by reverse-phase HPLC, and individual fractions were collected and given to DCs to prime naive CD8(+) T cells. Our current results show that we have been able to isolate HLA Class I molecules and acid-extract peptides with reasonable success, and we are in the process of doing specific bioassays with our priming cultures to identify positive fractions that may contain a new tumor-specific antigen. We have also done initial fractionations of the protein extracts from the tumor using reverse-phase HPLC, and used the individual fractions to prime naive CD4(+) T cells. Our results indicate that there is an abundance of proteins in our extracts, and currently, we are in the progress of beginning specific bioassays to identify positive fractions.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 1998
- Accession Number
- ADA354365
Entities
People
- Henry Kao
Organizations
- University of Pittsburgh